

URGENT FIELD SAFETY NOTICE
HELIOSTAR™ Balloon Ablation Catheter
(Product Code: D138904)

February 13, 2023

Dear Valued Customer,

At Biosense Webster, Inc. (“Biosense Webster”), we continuously monitor the performance of our products through our routine post-market surveillance process. You are receiving this letter because you have been identified as a user of the HELIOSTAR™ Balloon Ablation Catheter.

Biosense Webster has received complaints reporting Atrio-Esophageal Fistulas (AEF), while using the HELIOSTAR™ Balloon Ablation Catheter.

Through our investigation a review of each case was conducted and was found that one or more of the following factors contributed to the events:

- (1) Insufficient number of electrodes selected as posterior wall electrodes
- (2) Continuing to ablate on the posterior wall after esophageal temperature increases
- (3) Repeated, consolidation ablations in the same region of the posterior wall

HELIOSTAR™ Balloon Ablation Catheter can continue to be used as directed.

To minimize the risk of esophageal injury, it is critical to follow the HELIOSTAR™ Balloon Ablation Catheter Instructions For Use (IFU) as it includes important information about ablating near the esophagus. Biosense Webster would like to re-emphasize the following key recommendations (as detailed in IFU) to minimize the risk of esophageal injury:

1. Clearly identify which electrodes are facing the posterior wall of the left atrium. ⁽¹⁾
 - a. In all clinical trials with the HELIOSTAR catheter, a minimum of 3 electrodes were selected as posterior wall electrodes.
 - b. Based on bench top models, up to 5 electrodes can be facing the posterior wall of the left atrium
2. When ablating close to the esophagus consider reducing RF energy on the posterior wall by reducing the RF application time ⁽²⁾
3. Esophageal temperature monitoring was used in all clinical trials with HELIOSTAR and is the recommended method for esophageal monitoring. ⁽³⁾
4. If esophageal temperature rises > 2°C from baseline, stop the RF application to the adjacent and/or all active electrodes immediately. ⁽⁴⁾
5. When esophageal temperature monitoring is not possible, reduce RF energy, by reducing the RF duration on anterior and posterior wall electrodes. ⁽⁵⁾
6. Do not reapply RF energy on the posterior wall, especially if good impedance drop is observed, unless the posterior PV segments are reconnected. Do not reapply RF energy to the posterior wall until esophageal temperature returns to baseline. ⁽⁶⁾

Biosense Webster wants to present this information to you as part of our shared commitment to the safety of your patients. Please review this letter carefully and share it with any of your staff involved in such procedures.

The appropriate regulatory agencies have been notified and are aware that Biosense Webster is voluntarily providing this information.

What Actions Are Required:

1. Carefully review the information contained in this URGENT FIELD SAFETY NOTICE.
2. Ensure that anyone in your facility who needs to be aware of this notification reads the attached letter carefully.
3. Complete all fields of the attached Business Response Form and return it to [\[Enter Local Affiliate Information\]](#).

If you have additional questions about this letter, please contact your Biosense Webster representative.

Sincerely

Maria Jose Arana

Sr. Director, Quality & Compliance Biosense Webster, Inc.

31 Technology Drive, Suite 200. Irvine, CA 92618 USA

www.biosensewebster.com

References:

HELIOSTAR™ Balloon Ablation Catheter Instructions for Use M-5276-1052.01B (07June2021):

- (1) Section RECOMMENDATIONS (RF POWER), p. 6, fourth bullet point.
- (2) Section WARNINGS AND PRECAUTIONS, p.4, point 24.
- (3) Section RECOMMENDATIONS (RF POWER), p. 6, third bullet point.
- (4) Section RECOMMENDATIONS (RF POWER), p.6, fifth bullet point.
- (5) Section RECOMMENDATIONS (RF POWER), p.6, sixth bullet point.
- (6) Section RECOMMENDATIONS (RF POWER), p.6, fifth bullet point.



BUSINESS REPLY FORM

URGENT FIELD SAFETY NOTICE

HELIOSTAR™ Balloon Ablation Catheter
(Product Code: D138904)

Please complete this Business Reply Form (BRF) and return it to [\[Enter Local Affiliate Information\]](#) **within 3 business days upon receipt of this letter.**

Biosense Webster, a division of Johnson & Johnson Medical NV/SA

Attn: [\[Affiliate to Enter Representative or Recall Coordinator Name here\]](#)

Mailing Address: [\[Affiliate to Enter contact information here\]](#)

e-Mail Address: [\[Affiliate to Enter contact information here\]](#)

Fax Number (if applicable), affiliate could enter here.

Part 1. Please check and complete the following box to acknowledge receipt of notification:

I have read and understand the notification

Your Name/Title:	Facility/Business Name:
Signed*:	Date:
Facility/Business or shipping Address, City:	
Biosense Webster Sales Representative (if applicable):	
Date the notification was received:	
Telephone Number:	
<i>*Your signature provides confirmation that you have received and understood this notification.</i>	